Market Research Report

Global Cancer Immunotherapy Market Research Report: Forecast (2025-2030)

Cancer Immunotherapy Market Size - By Product Type Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies and Cancer Vaccines, Checkpoint Inhibitors, Others, By Cancer ...Type Lung Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, Melanoma, Colorectal Cancer, By Mechanism of Actions Active Immunotherapy, Passive Immunotherapy, By End Users Hospitals, Cancer Research Centers, Clinics) and Others Read more

  • Healthcare
  • Mar 2025
  • Pages 185
  • Report Format: PDF, Excel, PPT

US Reciprocal Tax Impact on Markets: Stay Informed with Expert Insights and Real-Time Updates

Market Definition

Immunotherapy is a medical procedure that makes use of specific immune system components to treat conditions like cancer. It strengthens the body's built-in defenses against the disease. It uses compounds created by the body or in a lab to strengthen the immune system in order to locate and eliminate cancer cells. Cancer immunotherapy is used to treat a variety of malignancies including melanoma, prostate, breast, colorectal, lung, head & neck and more.

Market Insights & Analysis: Global Cancer Immunotherapy Market (2025-30)

The Global Cancer Immunotherapy Market size was valued at around USD 134.4 billion in 2024 and is projected to reach USD 214.7 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2025-30.. The market is projected to experience significant growth due to several factors. One of the primary drivers is the increasing adoption of targeted therapy over traditional therapy, which has led to the emergence of biosimilars and increased demand for monoclonal antibodies (mAbs). The high prevalence of cancer also contributes to the rising inclination for such therapy, as immunotherapy drugs alter or boost the body's natural immune response to fight cancer. In conjugation, different immunotherapies, including CAR T-cell therapy, cancer vaccines, and immunomodulators, can be combined with other cancer treatments to achieve the best outcomes.

Report Coverage Details
Historical Years 2020–23
Forecast Years 2025–30
Market Value in 2024 USD 134.4 Billion
Market Value by 2030 USD 214.7 Billion
CAGR (2025–30) 8.12%
Leading Region North America
Top Key Players Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, ELI Lilly and Company, Janssen Global Services LLC, Johnson and Johnson, Merck, Novartis, Pfizer, F., Hoffmann-La Roche Ltd.
Segmentation By Product Type Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies and Cancer Vaccines, Checkpoint Inhibitors, Others, By Cancer Type Lung Cancer, Prostate Cancer,...Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, Melanoma, Colorectal Cancer, By Mechanism of Actions Active Immunotherapy, Passive Immunotherapy, By End Users Hospitals, Cancer Research Centers, Clinics) and others
Key Report Highlights
  • Market Dimensions & Projections
  • Pricing Evaluation
  • Recent Strategic Moves by Companies
  • Primary Stakeholders
  • Import/Export Trend Analysis
  • Competitive Landscape Assessment
  • Emerging Opportunities
  • Market Trends and Indicators

 

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

In fact, immunotherapy has proven to be a more targeted treatment than conventional therapies such as radiation & chemotherapy, helping to avoid potential damage to healthy tissue, which is usually common in these therapies. Furthermore, with promising response rates and the potential for durable responses, the success achieved by cancer immunotherapy is notably higher and likely to impact cancer patients positively, therefore aiding in enhancing the Global Cancer Immunotherapy Market size. Perhaps it is why the demand for such treatment methods is augmenting among cancer patients across the globe. Above all, the global market shall also expand due to the ongoing research & new approvals for such treatment methods. Thus, backed by these aspects, the market is projected to witness a substantial surge in its revenue in the coming years.

Global Cancer Immunotherapy Market Driver:

Increasing Frequency of Approvals Received by Novel Immunotherapies - Increasing acceptance of novel immunotherapies is expected to bode well for market expansion in the coming years. For instance, The U.S. FDA authorized a number of anti-PD-1/L1 antibodies between 2020 and 2022 for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate, and other malignancies. These antibodies include nivolumab, atezolizumab, avelumab, dostarlimab, and others. Therefore, the increased approval of immunotherapeutic drugs has fueled market development in the past few years.


Cancer Immunotherapy Market Size

Global Cancer Immunotherapy Market Challenge:

Possible Restraint: Side-effects Associated with the Cancer Immunotherapy

The numerous side effects associated with Immunotherapy are expected to reduce the number of prescriptions written for cancer. This is because treatments offered are linked to several adverse side effects, including gastrointestinal problems, insomnia, fatigue, and pain. These negative effects impact patients' overall quality of life, and managing them comes at an additional expense. Additionally, long-term immunotherapeutic drug use has been linked to severe organ deterioration and a rise in organ failure cases. Backed by these aspects, the market will likely impede in the coming years.

Global Cancer Immunotherapy Market Opportunity:

Growth Opportunity: Growing R&D Efforts to bring innovation in Cancer Immunotherapy Treatments

Numerous government and NGO initiatives that raise awareness and encourage further research are expected to aid the market's maturation. For example, the cancer study institute spent about USD 474 million on the analysis, supporting more than 120 clinical trials. Similarly, the Society for Immunotherapy of Cancer (SITC) is working to advance the understanding and use of oncology immunotherapy to improve patient results. Again, these organizations team with scientists and academics to develop cutting-edge immune therapy treatment plans.

Moreover, the raised funding for novel therapies is anticipated to accelerate R&D efforts to create cancer immunotherapy. For instance, the Cancer Grand Challenges program by the USA National Cancer Institute and Cancer Research UK provided USD13 million in funding to a team of Stanford scientists in June 2022. The funding aims to sponsor the activities such as the creation of new immunotherapies, research into extrachromosomal DNA, and examining early-stage cancers.

Global Cancer Immunotherapy Market Trend:

Key Trend: A Paradigm Shift from Conventional Chemotherapies to Immunotherapies Owing to Higher Efficacy of Newer Therapies

Increased research and development efforts in cancer immunotherapy have resulted in the development of advanced versions with better therapeutic efficacies. In fact, immuno-oncology has exhibited encouraging results, including improved survival and reduced toxicity. Besides, immunotherapies under research are anticipated to provide more treatment options and superior results than current medications. This has resulted in a paradigm shift from conventional chemotherapies to immunotherapies, consequently pushing the market forward. Furthermore, launching emerging medication classes targeting multiple myeloma receptors, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, is anticipated to boost the ancer immunotherapy market growth worldwide.

Global Cancer Immunotherapy Market (2025-30): Segmentation Analysis

The Global Cancer Immunotherapy Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2025–2030 at the global level. Based on the analysis, the market has been further classified as:

Based on Cancer Type:

  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Head and Neck Cancer
  • Melanoma
  • Colorectal Cancer

The lung cancer segment is the leading cancer type in the global cancer immunotherapy market by revenue and market share. This dominance is attributed to several key factors: the rising prevalence of lung malignancies, rising immunotherapy usage, increased awareness campaigns, and a strong pipeline of exploratory candidates. Additionally, there has been a marked increase in the use of immunotherapies for lung cancer, especially with the approval of new agents and combination regimens.

For instance, in December 2024, AstraZeneca’s Imfinzi (durvalumab) was approved as the first and only regimen for limited-stage small cell lung cancer (LS-SCLC) after chemotherapy and radiation, further strengthening the segment's position.

Global Cancer Immunotherapy Market Regional Projection

Geographically, the Global Cancer Immunotherapy Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

North America led the overall market in terms of revenue owing to the presence of numerous key players and the various strategic initiatives they have undertaken. Additionally, with the rising prevalence of diseases, numerous government & non-government organizations supporting cancer immunotherapy research activities have accelerated market growth over the past few years. For instance, among other prevailing deadly diseases, cancer has remained the leading cause of death in Canada for the last two decades, with 43% of residents likely to receive a cancer diagnosis in their lifetime. The study results from a collaboration among the Statistics Canada, the Canadian Cancer Society, and the Public Health Agency of Canada estimated that there would be 233,900 new cancer cases along with 85,100 cancer deaths in Canada in 2022. However, the figures apparently surged, with an estimated 229,200 cases and 84,600 deaths due to cancer in 2021.

Thus, the rising burden of numerous types of cancer in Canada necessitates suitable treatment, including cancer immunotherapy, thereby presenting a substantial business opportunity for the therapy as a market. Moreover, the increasing approval of novel drugs also contributes to regional market development. For instance, the U.S. FDA authorized Opdivo (nivolumab) to treat adult patients with NSCLC in April 2022.

Global Cancer Immunotherapy Market Industry Recent Development:

  • In 2024: AstraZeneca decided to pay USD 18 million to Immunai (biotechnology firm) to use New York-based firm’s AI model of the immune system for cancer drug trials.

Gain a Competitive Edge with Our Global Cancer Immunotherapy Market Report

  1. Global Cancer Immunotherapy Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps business organizations to gain a holistic understanding of market dynamics & make informed decisions.
  2. This report also highlights current market trends & future projections, allowing business organizations to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
  3. Global Cancer Immunotherapy Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, business organizations can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.

Don't Need a Global Report? Focus on reports for specific countries and regions

Frequently Asked Questions

   A. The Cancer Immunotherapy Market is expected to grow at a compound annual growth rate (CAGR) of around 8.12% from 2025 to 2030.

   A. Rise in R&D activities and high efficacy of newer therapies are the prime factors expected to drive the cancer immunotherapy market during 2025-30.

   A. Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, ELI Lilly and Company, Janssen Services LLC, Johnson and Johnson), Merck, Novartis, Pfizer, and F. Hoffmann-La Roche AG are the top players in the market.

   A. Lung cancer is anticipated to emerge as an area of remunerative opportunities for the leading players in the market.

   A. Globally, Asia-Pacific would provide lucrative prospects for the Cancer Immunotherapy market in the years ahead.

   A. Growing R&D efforts to create cancer immunotherapy are the growth opportunities driving the market through 2030.

   A. Side-effects associated with the cancer immunotherapy market is the possible restraint affecting the growth of the market.

   A. Cancer Immunotherapy Market size was valued at around USD 134.4 billion in 2024 and is projected to reach USD 214.7 billion by 2030.

  1. Research Basics
    1. Product Definition
    2. Research Process
    3. Assumptions
  1. Executive Summary
  2. Expert Verbatim- What our Experts Say?
  3. Global Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Oncolytic Viral Therapies and Cancer Vaccines
        4. Checkpoint Inhibitors
        5. Others
      2. By Cancer Type
        1. Lung Cancer
        2. Prostate Cancer
        3. Breast Cancer
        4. Ovarian Cancer
        5. Pancreatic Cancer
        6. Head and Neck Cancer
        7. Melanoma
        8. Colorectal Cancer
      3. By Mechanism of Actions
        1. Active Immunotherapy
        2. Passive Immunotherapy
      4. By End Users
        1. Hospitals
        2. Cancer Research Centers
        3. Clinics
      5. By Region
        1. North America
        2. Latin America
        3. Europe
        4. Middle East and Africa
        5. Asia-Pacific
      6. By Company
        1. Revenue Shares
        2. Strategic Factorial Indexing
        3. Competitor Placement in MarkNtel Quadrant
  4. North America Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
      2. By Cancer Type
      3. By End User
      4. By Mechanism of Actions
      5. By Country
        1. United States
        2. Canada
    3. United States Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By End User
        4. By Mechanism of Actions
    4. Canada Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By End User
        4. By Mechanism of Actions
  5. Latin America Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
      2. By Cancer Type
      3. By Mechanism of Actions
      4. By End User
      5. By Country
        1. Brazil
        2. Argentina
        3. Mexico
    3. Brazil Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
      3. By Product Type
      4. By Cancer Type
      5. By Mechanism of Actions
      6. By End User
    4. Argentina Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    5. Mexico Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
  6. Europe Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
      2. By Cancer Type
      3. By Mechanism of Actions
      4. By End User
      5. By Country
        1. France
        2. Germany
        3. Italy
        4. United Kingdom
        5. Spain
    3. France Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    4. Germany Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    5. Italy Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    6. United Kingdom Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    7. Spain Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
  7. Middle East and Africa Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
      2. By Cancer Type
      3. By Mechanism of Actions
      4. By End User
      5. By Country
        1. UAE
        2. Saudi Arabia
        3. Turkey
        4. South Africa
    3. UAE Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    4. Saudi Arabia Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    5. Turkey Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
        2. Units Sold
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    6. South Africa Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
        2. Units Sold
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
  8. Asia-Pacific Cancer Immunotherapy Market Analysis, 2020- 2030F
    1. Market Size & Analysis
      1. Market Revenue
    2. Market Share & Analysis
      1. By Product Type
      2. By Cancer Type
      3. By Mechanism of Actions
      4. By End User
      5. By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. South Korea
    3. China Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
      3. By Product Type
      4. By Cancer Type
      5. By Mechanism of Actions
      6. By End User
    4. India Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    5. Japan Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    6. Australia Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
    7. South Korea Cancer Immunotherapy Market Analysis, 2020- 2030F
      1. Market Size & Analysis
        1. Market Revenue
      2. Market Share & Analysis
        1. By Product Type
        2. By Cancer Type
        3. By Mechanism of Actions
        4. By End User
  9. Global Cancer Immunotherapy Market Policies, Regulations, Product Standards  
  10. Global Cancer Immunotherapy Market Trends & Insights
  11. Global Cancer Immunotherapy Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  12. Global Cancer Immunotherapy Market Hotspot & Opportunities
  13. Global Cancer Immunotherapy Market Key Strategic Imperatives for Success & Growth
  14. Global Competition Outlook
    1. Competition Matrix
      1. Product Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target Cancer Types
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, Product Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Amgen Inc.,
      2. Astrazeneca,
      3. Bayer AG,
      4. Bristol-Myers Squibb,
      5. ELI Lilly and Company,
      6. Janssen Global Services LLC
      7. Johnson and Johnson),
      8. Merck,
      9. Novartis,
      10. Pfizer, F.
      11. F. Hoffmann-La Roche AG
  15. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Request Sample Talk to our Consultant Request Customization
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Related Reports